Skip to main content

Breakthrough in Development of Targeted Drug for Leukemia

Leukemia is the cancer of blood forming tissue. A person with leukemia suffers from an abnormal production of blood cells. Healthy blood cells usually die after a while and are replaced by new cells produced in the bone marrow, but the abnormal blood cells don’t die when they should and accumulate, occupying more space and impeding the growth of healthy WBCs by crowding out space in the blood, compromising your immune system.

Leukemia is getting a lot of social media attention right now after President Trump’s new healthcare bill was introduced. The bill seemed to be removing support for people with preexisting conditions which could be disastrous for those suffering from leukemia as treatments are incredibly expensive. During a CNN interview, an Alabama republican, Representative Mo Brooks was quoted saying something along the lines of Healthy people have done the right thing and have led the right lifestyle to keep their bodies healthy so they should not have to pay more for insurance.

This begs the question what did kids with leukemia and other chronic diseases do wrong that they will not be able to avail the benefits of affordable healthcare. Isn’t it ridiculous to say that the people who can’t afford the cost of their own medical care have nobody to blame but themselves? There are a lot of fundraisers and awareness campaigns for Leukemia happening recently. Pharmaceutical companies are also working hard on developing drugs that target leukemia which will be much cheaper than the conventional treatment methods currently employed.

The FDA has recently approved the first targeted drug for patients with an aggressive form of Leukemia. The drug is currently approved for adults who have acute myeloid Leukemia, aka AML, who have a genetic mutation called FLT3. Each year in the US, AML kills more than 10,000 people and about 20,000 are diagnosed with it. Novartis has announced that the price without insurance will be USD 14,990 for four weeks of treatment.

According to Market Data Forecast’s research report, the Leukemia therapeutics market is growing at a rate of 9.5% and is expected to grow even faster in response to increasing demand and technological advancements in the field of cancer study. North America currently holds the highest share of the market and is followed by Europe. This dominance by North America is due to rising prevalence of the disease, growing awareness, and lots of government support. The Asia pacific market however is growing at a really fast rate due to factors such as rising consumer market and increasing ageing population in the developing nations of the region.

The prominent players in the Leukemia therapeutics market include Pfizer, Novartis, Roche, GSK, Eisai, Biogen, Clavis Pharma, Cephalon, Genmab, and Celgene. The companies are working on targeted drugs for leukemia like Novartis’ Rydapt to significantly lower the cost of Leukemia treatments and ensure that the treatment is available to everybody.

For updates on the developments and breakthroughs in the Healthcare field follow us @MDFinsights. To view our complete list of syndicated research reports visit us at http://www.marketdataforecast.com

Leave a Reply

Your email address will not be published. Required fields are marked *